Arsanis Inc (NASDAQ:ASNS) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price objective of $26.50 for the company and are expecting that the company will post ($3.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Arsanis an industry rank of 184 out of 265 based on the ratings given to related companies.
A number of analysts have recently commented on the company. ValuEngine raised Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Cantor Fitzgerald assumed coverage on Arsanis in a research note on Wednesday. They issued an “overweight” rating and a $26.00 price target for the company. Piper Jaffray Companies assumed coverage on Arsanis in a research note on Monday, December 11th. They issued an “overweight” rating and a $23.00 price target for the company. Cowen assumed coverage on Arsanis in a research note on Monday, December 11th. They issued an “outperform” rating for the company. Finally, Citigroup started coverage on Arsanis in a research note on Monday, December 11th. They issued a “buy” rating and a $27.00 price target for the company.
A number of hedge funds and other institutional investors have recently bought and sold shares of ASNS. Monashee Investment Management LLC bought a new stake in Arsanis during the 4th quarter worth approximately $191,000. Millennium Management LLC bought a new stake in Arsanis during the 4th quarter worth approximately $299,000. Landscape Capital Management L.L.C. bought a new stake in Arsanis during the 4th quarter worth approximately $504,000. Finally, Sphera Funds Management LTD. bought a new stake in Arsanis during the 4th quarter worth approximately $3,436,000.
Shares of Arsanis (NASDAQ:ASNS) traded up $0.53 during mid-day trading on Friday, hitting $13.77. The stock had a trading volume of 4,526 shares, compared to its average volume of 10,898. Arsanis has a one year low of $10.40 and a one year high of $19.73.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/18/zacks-brokerages-set-26-50-price-target-for-arsanis-inc-asns.html.
Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.